专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP0736545A3 Dextrin ester of fatty acids and use thereof 失效
标题翻译：糊精和脂肪酸及其酯的使用
公开(公告)号：EP0736545A3
公开(公告)日：1997-06-18
申请号：EP96105259.4
申请日：1996-04-02
申请人： Chiba Flour Milling Co., Ltd. , KOSE CORPORATION
发明人： Suzuki, Takanao , Amano, Isaburo , Chiba, Koji , Tofukuji, Ruka
IPC分类号： C08B31/04 , C09D11/14 , A61K7/48
CPC分类号： C08B30/18 , A61K8/06 , A61K8/732 , A61K2800/43 , A61Q1/02 , A61Q1/06 , A61Q1/10 , A61Q19/00 , C08B31/04 , C09D5/04 , C09D11/03
摘要： Disclosed are a dextrin ester of fatty acids in which dextrin has an average saccharide polymerization degree of 3 to 150, the fatty acids comprise a straight chain fatty acid having 8 to 22 carbon atoms and at least one fatty acid selected from the group consisting of branched fatty acids having 4 to 26 carbon atoms, unsaturated fatty acids having 6 to 30 carbon atoms and straight chain saturated fatty acids having 6 or less carbon atoms, and the substitution degree of fatty acids per glucose unit is 1.0 to 3.0; and a gelling agent, a composition and a base comprising the ester, the ester being excellent in thixotropic property, moisture retaining property, emulsifiability, adhesion and dispersibility, and therefore suitably used for cosmetics, printing ink, coatings, etc.

2. 发明公开

EP0477050A3 LPS-producing bacteria, LPSs, and LPS-containing medicines and veterinary medicines 失效
标题翻译： LPS产生细菌，LPSS和含LPS的药物和兽药
公开(公告)号：EP0477050A3
公开(公告)日：1993-03-17
申请号：EP91402275.1
申请日：1991-08-20
申请人： CHIBA FLOUR MILLING CO. LTD. , Soma, Gen-Ichiro , Mizuno, Den'Ichi
发明人： Soma, Gen-Ichiro , Yoshimura, Kiyoshi , Tsukioka, Daisuke , Mizuno, Den'Ichi , Oshima, Haruyuki Tategaoka-Danchi 2-10-513
IPC分类号： C12N1/20 , C12P19/04 , A61K31/735
CPC分类号： C12R1/425 , A61K35/74 , A61K45/05 , C12P19/04 , C12R1/01 , Y02A50/475 , Y10S514/885
摘要： Novel LPS having the following physical properties, novel bacilli providing those LPS, and novel immunity stimulators, analgesics, and antiwithdrawal agents, and novel veterinary immunity stimulators, analgesics, and antiwithdrawal agents containing LPS selected from the group consisting of those LPSs and mixtures thereof.
LPS1
Dominant molecular weight: 5,000 ± 1,000 as determined by SDS-PAGE method Phosphorus number: 2 ± 1 / 5,000 (m.w.) Hexosamine number: 9 ± 1 / 5,000 (m.w.) KDO number: 2 ± 1 / 5,000 (m.w.)
LPS2
Dominant molecular weight: 6,500 ± 2,500 as determined by SDS-PAGE method Phosphorus number: 1 to 2 / 5,000 (m.w.) Hexosamine number: 7 ± 1 / 5,000 (m.w.) KDO number: 1 to 2 / 5,000 (m.w.)
LPS3
Dominant molecular weight: 6,500 ± 2,500 as determined by SDS-PAGE method Phosphorus number: 2 ± 1 / 5,000 (m.w.) Hexosamine number: 5 ± 1 / 5,000 (m.w.) KDO number: 2 ± 1 / 5,000 (m.w.)

3. 发明公开

EP0472467A2 LPS-Containing analgesics and veterinary analgesics 失效
标题翻译： LPS enthaltende Analgetika undtierärztlicheAnalgetika。
公开(公告)号：EP0472467A2
公开(公告)日：1992-02-26
申请号：EP91402276.9
申请日：1991-08-20
申请人： CHIBA FLOUR MILLING CO. LTD. , Soma, Gen-Ichiro , Mizuno, Den'Ichi
发明人： Soma, Gen-Ichiro , Yoshimura, Kiyoshi , Tsukioka, Daisuke , Mizuno, Den'Ichi , Oshima, Haruyuki Tategaoka-Danchi 2-10-513
IPC分类号： A61K37/20
CPC分类号： C12R1/425 , A61K35/74 , A61K45/05 , C12P19/04 , C12R1/01 , Y02A50/475 , Y10S514/885
摘要： An analgesic composition comprising an effective amount of at least one member of LPS whose macrophage activation ED₅₀ is 0.4 - 100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro , and plotting the macrophage activation ability (%) along the axis of ordinate wherein the ability is estimated to be 0 % in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100 % is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, high cholesterol level of said animal is prevented or cured; and
a method of treating pain of an animal comprising administration to said animal an amount of the above composition effective to prevent or cure the pain of said animal.
摘要翻译：一种镇痛组合物，其包含有效量的至少一种LPS成员，其巨噬细胞活化ED 50为0.4-100ng / ml培养液，其鲎试验阳性LPS含量在通过测定 LPS激活体外培养的巨噬细胞的TNF产生，并绘制沿纵坐标轴的巨噬细胞活化能力（％），其中在与巨噬细胞产生的TNF的量相对应的情况下，该能力估计为0％没有添加LPS，并且赋予巨噬细胞活化能力100％，其提供由巨噬细胞产生的TNF的最大和恒定量，并沿着横坐标绘制LPS的鲎试验阳性LPS含量以对数标度绘制，与药学或兽医学上可接受的载体混合，使得当施用于动物时，防止所述动物的高胆固醇水平或治愈; 以及治疗动物疼痛的方法，包括向所述动物施用一定量的上述组合物，其有效预防或治愈所述动物的绒毛。

4. 发明公开

EP0462021A2 Cholesterol-lowering agents and veterinary cholesterol-lowering agents 失效
标题翻译： Den。。。。。。。。。。。。。。。。。。。。。。。
公开(公告)号：EP0462021A2
公开(公告)日：1991-12-18
申请号：EP91401622.5
申请日：1991-06-17
申请人： CHIBA FLOUR MILLING CO. LTD. , Soma, Gen-Ichiro , Mizuno, Den'Ichi
发明人： Soma, Gen'Ichiro , Yoshimura, Kiyoshi , Tsukioka, Daisuke , Mizuno, Den'Ichi , Oshima, Haruyuki
IPC分类号： A61K37/20 , A61K35/78 , A61K35/74
CPC分类号： A61K36/02 , A61K36/06 , A61K36/07 , A61K36/899 , A61K2300/00
摘要： A cholesterol-lowering composition comprising an effective amount of at least one member of LPS whose macrophage activation ED₅₀ is 0.4 - 100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro , and plotting the macrophage activation ability (%) along the axis of ordinate wherein the ability is estimated to be 0 % in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100 % is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, high cholesterol level of said animal is prevented or cured; and
a method of treating high cholesterol level of an animal comprising administration to said animal an amount of the above composition effective to prevent or cure the high cholesterol level of said animal.
摘要翻译：一种胆固醇降低组合物，其包含有效量的至少一种LPS成分，其巨噬细胞活化ED 50为0.4-100ng / ml培养液，其鲎试验阳性LPS含量在通过测定能力制备的乙状曲线上观察到的LPS以激活体外培养的巨噬细胞的TNF生产力，并绘制沿纵坐标轴的巨噬细胞活化能力（％），其中在对应于由TNFα产生的TNF的量的情况下，该能力估计为0％没有添加LPS的巨噬细胞，100％被赋予巨噬细胞活化能力，其提供由巨噬细胞产生的TNF的最大和恒定量，并沿着横坐标绘制LPS的鲎试验阳性LPS含量为对数与药学或兽医学上可接受的载体混合，使得当施用于动物时，所述动物的高胆固醇水平是预先通风或治愈; 以及治疗动物的高胆固醇水平的方法，包括向所述动物施用一定量的上述有效预防或治愈所述动物的高胆固醇水平的组合物。

5. 发明公开

EP0472467A3 LPS-Containing analgesics and veterinary analgesics 失效
标题翻译：含LPS的肠化学和兽医学
公开(公告)号：EP0472467A3
公开(公告)日：1993-03-17
申请号：EP91402276.9
申请日：1991-08-20
申请人： CHIBA FLOUR MILLING CO. LTD. , Soma, Gen-Ichiro , Mizuno, Den'Ichi
发明人： Soma, Gen-Ichiro , Yoshimura, Kiyoshi , Tsukioka, Daisuke , Mizuno, Den'Ichi , Oshima, Haruyuki Tategaoka-Danchi 2-10-513
IPC分类号： A61K37/20
CPC分类号： C12R1/425 , A61K35/74 , A61K45/05 , C12P19/04 , C12R1/01 , Y02A50/475 , Y10S514/885
摘要： An analgesic composition comprising an effective amount of at least one member of LPS whose macrophage activation ED₅₀ is 0.4 - 100 ng/ml of culture solution in terms of its limulus test-positive LPS content observed on a sigmoid curve prepared by determining the ability of the LPS to activate the TNF productivity of macrophage cultured in vitro , and plotting the macrophage activation ability (%) along the axis of ordinate wherein the ability is estimated to be 0 % in the case where it corresponds to the quantity of TNF produced by macrophage with no LPS added thereto, and 100 % is assigned to the macrophage activation ability which provides the maximal and constant quantity of TNF produced by the macrophage and plotting the limulus test-positive LPS content of the LPS along the axis of abscissa on a logarithmic scale, in admixture with a pharmaceutically or veterinarily acceptable carrier, such that when administered to an animal, high cholesterol level of said animal is prevented or cured; and
a method of treating pain of an animal comprising administration to said animal an amount of the above composition effective to prevent or cure the pain of said animal.

6. 发明授权

EP2537865B1 NOVEL DEXTRIN FATTY ACID ESTER THAT DOES NOT CAUSE GELATION OF LIQUID OIL, AND USES THEREOF 有权
标题翻译：新的，而不是为液态油凝胶化领先糊精脂肪酸酯及其应用
公开(公告)号：EP2537865B1
公开(公告)日：2017-02-08
申请号：EP11744414.1
申请日：2011-02-16
申请人： Chiba Flour Milling Co., Ltd , Kosé Corporation
发明人： KOIKE, Hideaki , SUZUKI, Takanao , TSUKIOKA, Daisuke , MIYAGAWA, Satsuki , TOMITA, Yuriko , IGARASHI, Keiji
IPC分类号： C08B31/04 , A61K8/60 , A61K8/73 , A61K47/26 , A61K47/36 , A61Q1/10 , A61Q1/12 , A61Q3/02 , A61Q5/00 , A61Q17/04 , A61Q19/00 , C07H13/06 , C09D7/12 , C09D11/00 , C09D201/00 , C11C3/04
CPC分类号： C08B31/04 , A61K8/73 , A61K2800/10 , A61Q19/00 , C07H13/06 , C08B30/18 , C09D7/45 , C09D11/14 , C11C3/00
摘要： An object of the present invention is to provide novel dextrin fatty acid ester that is excellent in tackiness and useful as a base for cosmetics and the like. The novel dextrin fatty acid ester is prepared by esterification between dextrin and fatty acids, wherein the dextrin has an average degree of glucose polymerization of 3 to 150; the fatty acids comprise more than 50 mol% and 100 mol% or less, based on the total amount of the fatty acids, of one or more saturated branched fatty acids having 4 to 26 carbon atoms, and 0 mol% or more and less than 50 mol%, based on the total amount of the fatty acids, of one or more fatty acids selected from the group consisting of saturated linear fatty acids having 2 to 22 carbon atoms, unsaturated linear or branched fatty acids having 6 to 30 carbon atoms, and saturated or unsaturated cyclic fatty acids having 6 to 30 carbon atoms; and the degree of substitution by the fatty acids is 1.0 to 3.0 per glucose unit.

7. 发明授权

EP0571724B1 Stabilizer for phospholipid vesicles 失效
标题翻译：稳定的磷脂囊泡
公开(公告)号：EP0571724B1
公开(公告)日：1997-06-04
申请号：EP93104031.5
申请日：1993-03-12
申请人： CHIBA FLOUR MILLING CO. LTD.
发明人： Akihisa, Saitoh , Kiyoshi, Yoshimura , Takanao, Suzuki , Mikimasa, Takisada , Shinji, Takeoka , Hiromi, Sakai , Eishun, Tsuchida
IPC分类号： C07H15/04 , C07H15/10 , C07H15/06 , C07J17/00 , A61K9/127
CPC分类号： C07H15/06 , A61K9/1271 , A61K9/1272 , C07H15/04 , C07H15/10 , C07J17/005

8. 发明公开

EP0751170A2 Silicone derivatives, their production and use 失效
标题翻译：有机硅衍生物及其生产和使用
公开(公告)号：EP0751170A2
公开(公告)日：1997-01-02
申请号：EP96110471.8
申请日：1996-06-28
申请人： Chiba Flour Milling Co., Ltd.
发明人： Ohno, Hiroyuki , Kawahara, Natsue , Amano, Isaburo , Suzuki, Takanao , Chiba, Koji
IPC分类号： C08G77/26 , C08G77/388
CPC分类号： A61K8/898 , A61K47/34 , A61K2800/57 , A61Q19/00 , C08G77/388
摘要： Disclosed are amino silicone derivatives having triazinyl groups or pyrimidinyl groups bound to amino groups of amino silicones, their production and use, said silicone derivatives being able to gel silicone oil or to increase the viscosity thereof stably and homogeneously, and therefore being useful as bases for cosmetics, pharmaceutical preparations and industrial materials.
摘要翻译：公开了具有与氨基硅氧烷的氨基结合的三嗪基或嘧啶基的氨基硅氧烷衍生物，它们的制备和用途，所述硅氧烷衍生物能够凝胶化硅油或增加其稳定和均匀的粘度，因此可用作化妆品，药物制剂和工业材料。

9. 发明公开

EP0571724A1 Stabilizer for phospholipid vesicles 失效
标题翻译： Phospholipidvesikeln的稳定剂。
公开(公告)号：EP0571724A1
公开(公告)日：1993-12-01
申请号：EP93104031.5
申请日：1993-03-12
申请人： CHIBA FLOUR MILLING CO. LTD.
发明人： Akihisa, Saitoh , Kiyoshi, Yoshimura , Takanao, Suzuki , Mikimasa, Takisada , Shinji, Takeoka , Hiromi, Sakai , Eishun, Tsuchida
IPC分类号： C07H15/04 , C07H15/10 , C07H15/06 , C07J17/00 , A61K9/127
CPC分类号： C07H15/06 , A61K9/1271 , A61K9/1272 , C07H15/04 , C07H15/10 , C07J17/005
摘要： An oligosaccharide lipid is provided which has 2 to 20 saccharide units, and has a hydrophobic group linked by an ether linkage to an anomer carbon on a reducing end group. A stabilizer for a phospholipid vesicle is also provided which comprises an oligosaccharide derivative having 2 to 20 saccharide units, and having a hydrophobic group linked by an amide linkage or an ether linkage to an anomer carbon on a reducing end group constituted of an aldose.
摘要翻译：提供寡糖脂质，其具有2至20个糖单元，并且具有通过醚键连接至还原端基上的端基碳的疏水基团。还提供了一种磷脂囊泡的稳定剂，其包含具有2至20个糖单元的寡糖衍生物，并且具有通过由醛糖构成的还原端基上的与酰胺键或醚键连接的端基异构体的疏水基团。

10. 发明公开

EP0533517A1 LPS-containing anti-withdrawal agents 失效
标题翻译： LPS enthaltenes Anti-Entzugsmittel。
公开(公告)号：EP0533517A1
公开(公告)日：1993-03-24
申请号：EP92402319.5
申请日：1992-08-20
申请人： CHIBA FLOUR MILLING CO. LTD. , Soma, Gen-Ichiro , Mizuno, Den'Ichi
发明人： Tsukioka, Daisuke , Yoshimura, Kiyoshi , Oshima, Haruyuki , Soma, Gen-Ichiro , Mizuno, Den'Ichi
IPC分类号： A61K31/715 , C12P19/04
CPC分类号： C12P19/04 , A61K31/715 , Y10S435/822 , Y10S514/885
摘要： Novel antiwithdrawal agents and veterinary antiwithdrawal agents are disclosed which contain LPS representative of which having the following physical properties:
LPS1

Dominant molecular weight: 5,000 ± 1,000 as determined by SDS-PAGE method
Phosphorus number: 2 ± 1 / 5,O00 (m-w.)
Hexosamine number: 9 ± 1 / 5,000 (m.w.)
KDO number: 2 ± 1 / 5,000 (m.w.)

LPS2

Dominant molecular weight: 6,500: ± 2,500 as determined by SDS-PAGE method
Phosphorus number: 1 to 2 / 5,000 (m.w.)
Hexosamine number: 7 ± 1 / 5,000 (m.w.)
KDO number: 1 to 2 / 5,000 (m.w.)

LPS3

Dominant molecular weight: 6,500 ± 2,500 as determined by SDS-PAGE method
Phosphorus number: 2 ± 1 / 5,000 (m.w.)
Hexosamine number: 5 ± 1 / 5,000 (m.w.)
KDO number: 2 ± 1 / 5,000 (m.w.)
摘要翻译：公开了含有代表具有以下物理性质的LPS的新型抗抽出剂和兽用抗抽穗剂：LPS1主要分子量：5,000 +/- 1,000，通过SDS-PAGE法测定磷数：2 +/- 1 / 5,000 （mw。）己糖胺数：9 +/- 1 / 5,000（mw）KDO数：2 +/- 1 / 5,000（mw）LPS2主要分子量：6,500：+/- 2,500，通过SDS-PAGE法测定磷数：1〜2 / 5,000（mw）己糖胺数：7 +/- 1 / 5,000（mw）KDO数：1〜2 / 5,000（mw）LPS3主要分子量：6,500 +/- 2,500，通过SDS-PAGE法测定磷数：2 +/- 1 / 5,000（mw）己糖胺数：5 +/- 1 / 5,000（mw）KDO数：2 +/- 1 / 5,000（mw）e

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式